10 Low Risk High Reward Stocks Set to Triple by 2030

4. Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Number of Hedge Fund Holders: 21

Potential upside: 330.50%

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) develops innovative immunotherapy treatments targeting key immune cell proteins. Based in South San Francisco, the company is pushing forward several drug candidates through smart, cost-effective strategies. Its main drug, soquelitinib (CPI-818), shows promising results for both cancer and autoimmune conditions.

As of December 31, 2024, Corvus doubled its cash reserves to $52 million, up from $27.1 million the previous year. Meanwhile, early warrant exercises brought in $18.6 million, with another potential $41 million available, and these finances should keep the company running into Q1 2026. Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) spent more on R&D last year ($19.4 million compared to $16.5 million in 2023), mostly on soquelitinib development. The company posted a $63.3 million net loss, which includes a $33.4 million non-cash hit from warrant liability and $3.2 million from its Angel Pharmaceuticals partnership. Furthermore, stock compensation was at $3 million for the year.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) is now running a Phase 3 trial of socalitinib for relapsed peripheral T-cell lymphoma. Earlier Phase 1 results were promising, with 39% of patients responding and 26% showing a complete response. Moreover, its Phase 1 atopic dermatitis trial looks encouraging, with results beating placebo and safety data. The company is planning a Phase 2 solid tumor study and working with the NIH on a trial for ALPS, in addition to more atopic dermatitis programs expected to start later this year.

With its unique oral ITK inhibitor, advancing clinical work, and solid cash position, Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stands out in the list of the best low risk stocks.